DARS,编码天冬氨酰-tRNA合成酶,与各种癌症的发病机理有关,包括肾细胞癌,胶质母细胞瘤,结肠癌,还有胃癌.其在BCR/ABL1阴性骨髓增殖性肿瘤(MPNs)中的作用,然而,仍未探索。本研究旨在通过免疫组织化学分析阐明MPNs患者(PV23,ET19,PMF16)中DARS的表达,并使用流式细胞术检查循环免疫细胞和细胞因子的分布。我们的发现表明,与对照组相比,所有MPN亚型中DARS的蛋白水平均显着过表达(P<0.05)。值得注意的是,在MPNs患者中,升高的DARS表达与脾肿大相关.DARS的表达与CD4+T细胞(R=-0.451,P=0.0004)和CD4+T/CD8+T细胞比值(R=-0.3758,P=0.0040)呈负相关,以及CD68+肿瘤相关巨噬细胞(R=0.4037,P=0.0017)。相反,与IL-2呈正相关(R=0.5419,P<0.001),IL-5(R=0.3161,P=0.0166),IL-6(R=0.2992,P=0.0238),和IFN-γ(R=0.3873,P=0.0029)。这些发现强调了MPNs患者DARS表达与特定临床特征之间的显著关联。以及免疫细胞组成。进一步研究DARS与MPN中免疫微环境之间的相互作用可以揭示MPN发病机理和免疫失调的潜在机制。
DARS, encoding for aspartyl-tRNA synthetase, is implicated in the pathogenesis of various cancers, including renal cell carcinoma, glioblastoma, colon cancer, and gastric cancer. Its role in BCR/ABL1-negative myeloproliferative neoplasms (MPNs), however, remains unexplored. This study aimed to elucidate the expression of DARS in patients with MPNs (PV 23, ET 19, PMF 16) through immunohistochemical analysis and to examine the profiles of circulating immune cells and cytokines using flow cytometry. Our findings indicate a significant overexpression of DARS in all MPNs subtypes at the protein level compared to controls (P < 0.05). Notably, elevated DARS expression was linked to splenomegaly in MPNs patients. The expression of DARS showed a negative correlation with CD4+ T cells (R = - 0.451, P = 0.0004) and CD4+ T/CD8+ T cell ratio (R = - 0.3758, P = 0.0040), as well as with CD68+ tumor-associated macrophages (R = 0.4037, P = 0.0017). Conversely, it was positively correlated with IL-2 (R = 0.5419, P < 0.001), IL-5 (R = 0.3161, P = 0.0166), IL-6 (R = 0.2992, P = 0.0238), and IFN-γ (R = 0.3873, P = 0.0029). These findings underscore a significant association between DARS expression in MPNs patients and specific clinical characteristics, as well as immune cell composition. Further investigation into the interplay between DARS and the immune microenvironment in MPNs could shed light on the underlying mechanisms of MPNs pathogenesis and immune dysregulation.